Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease - Takeaways - MDSpire

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

  • By

  • Vasantharaja Raguraman

  • Miranda Mysinger

  • Mohit Verma

  • Shanid Mohiyuddin

  • Nashwan Jabbour

  • Melissa Kesler

  • Trupti Joshi

  • Senthilnathan Palaniyandi

  • Gerhard C. Hildebrandt

  • June 11, 2026

  • 0 min

Share

  • 1

    Acalabrutinib, a selective BTK inhibitor, significantly improves survival and clinical outcomes in murine models of chronic graft-versus-host disease.

  • 2

    Treatment with acalabrutinib reduces skin pathology, dermal thickness, and mast cell numbers in models of sclerodermatous chronic GVHD.

  • 3

    In vitro studies show that acalabrutinib effectively inhibits pro-inflammatory chemokines CCL2, CCL3, and CCL4 in a dose-dependent manner.

  • 4

    RNA sequencing reveals that acalabrutinib treatment downregulates genes associated with keratinization in the skin.

  • 5

    The findings support further investigation of acalabrutinib as a therapeutic option for patients with chronic graft-versus-host disease.

Original Source(s)

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

  • by Vasantharaja Raguraman, Miranda Mysinger, Mohit Verma, Shanid Mohiyuddin, Nashwan Jabbour, Melissa Kesler, Trupti Joshi, Senthilnathan Palaniyandi, Gerhard C. Hildebrandt

  • June 11, 2026

Related Content

Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches

The cells of origin of the chemotherapy-curable malignancies are highly sensitive to cytotoxic chemotherapy-mediated cell death

The enigma of inverted lymph node architecture in pigs: insights into immune function and vaccination design